Oryzon Genomics S.A. (ORYZF)
OTCMKTS
· Delayed Price · Currency is USD
3.030
0.00 (0.00%)
At close: Apr 23, 2025
Oryzon Genomics Employees
Oryzon Genomics had 46 employees as of December 31, 2023. The number of employees increased by 2 or 4.78% compared to the previous year.
Employees
46
Change (1Y)
2
Growth (1Y)
4.78%
Revenue / Employee
$162,097
Profits / Employee
-$80,741
Market Cap
238.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
Oryzon Genomics News
- 8 days ago - ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat - GlobeNewsWire
- 6 weeks ago - ORYZON to Provide Corporate Progress Updates at Several Events in March-April - GlobeNewsWire
- 7 weeks ago - Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat - GlobeNewsWire
- 2 months ago - ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 2 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024 - GlobeNewsWire
- 2 months ago - ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - GlobeNewsWire
- 3 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - GlobeNewsWire
- 3 months ago - ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome - GlobeNewsWire